StockData
AGPUNasdaqFinance ServicesFiscal year ends December 31

Axe Compute Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$8.09+0.41 (+5.34%)

Close on Oct 19, 2026

Market cap
$159.26M
P/E (TTM)
–
Dividend yield
–

About Axe Compute

Finance Services, SIC 6199

Axe Compute Inc. is an enterprise infrastructure and biomedical technology company operating through two main divisions: Compute Services and Treasury Management, and Drug Discovery Services. In its primary compute segment, the company provides on-demand access to high-performance GPU capacity for artificial intelligence, machine learning, and high-performance computing workloads through a decentralized network model, while actively managing a native token treasury. Its legacy drug discovery unit utilizes artificial intelligence, a biobank of tumor samples, and three-dimensional tissue models to support cancer drug development and evaluate potential therapeutics. The company serves enterprise clients, artificial intelligence developers, large-scale workload operators, and biopharmaceutical companies.

The company operates an asset-light compute network spanning over two hundred global locations, delivering access to more than 435,000 GPUs sourced primarily from third-party hardware suppliers. It also maintains a certified laboratory in Pittsburgh to conduct oncology testing and model development. The provided report does not state the location of the company's corporate headquarters.

Summary of the business section of Axe Compute's latest annual report, written by StockData.

Company profile

Company

Legal name
Axe Compute Inc.
Headquarters
Pittsburgh, PA
Address
91 43rd Street, Suite 110 15201
Phone
(412) 432-1500
Employees
13, Dec 31, 2025
Industry
Finance Services
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Pittsburgh, Pennsylvania

Stock & identifiers

Ticker
AGPU
Exchange
Nasdaq
Shares outstanding
12M, Aug 13, 2026
Public float
$7.97M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Sep 30, 2025; 1-for-20 reverse, May 15, 2023; 1-for-20 reverse, Apr 24, 2023; 1-for-10 reverse, Nov 15, 2019; 1-for-10 reverse, Oct 29, 2019; 1-for-25 reverse, Nov 14, 2016; 1-for-25 reverse, Oct 28, 2016; 1-for-75 reverse, Nov 12, 2014; 1-for-75 reverse, Oct 28, 2014
SEC CIK
1446159
CUSIP
74039M408
ISIN
US74039M4087
LEI
549300UQE748N2H9LE74
EIN
33-1007393

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Christopher MiglinoCEO and Director1,800
Raymond F. VennareChief Executive Officer, Director19,677
Joshua BlacherCo-Chief Financial Officer15,856
Jeremy Reese Yaukey-WitterCo-Chief Financial Officer1,138
Kyle Robert OkamotoPresident244,389
Thomas Louis McLaughlinChief Investment Officer–
Charles Lee Nuzum SrDirector22,808
Matthew HawrylukDirector13,443
Clair Gregory St. SrDirector17,566
Daniel E. HandleyDirector12,756
Theodore ZhuDirector7,564
Shawn MatthewsDirector1,166
Veena RaoDirector9,177
Nancy Chung-WelchDirector83,993

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024
PEO1
$525.00K$525.00K$423.27K$4–
FY2024
PEO2
$0$0$423.27K$4–
FY2023
PEO1
$525.00K$525.00K$425.30K$17–
FY2023
PEO2
$0$0$425.30K$17–
FY2022
PEO1
$121.63K$121.63K$511.87K$32–
FY2022
PEO2
$1.18M$1.18M$511.87K$32–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“We had 13 full-time employees and 1 part-time employee as of December 31, 2025.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 17, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 11, 2025Name changeName changed from Predictive Oncology Inc. to Axe Compute Inc.
Jul 11, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 11, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 22, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 20, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 8, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 5, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 10, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 13, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 18, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 1, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 15, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 30, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 31, 2020Late filingNotification of late filing
Nov 15, 2019Late filingNotification of late filing
Aug 14, 2019Late filingNotification of late filing
Jun 4, 2019Name changeName changed from Precision Therapeutics Inc. to Predictive Oncology Inc.
May 17, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 10, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 2, 2019Late filingNotification of late filing
Nov 19, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 29, 2018MergerRegistration of securities for a merger or exchange offer (S-4)
Apr 26, 2018Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 6, 2018Name changeName changed from Skyline Medical Inc. to Precision Therapeutics Inc.
Nov 24, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 12, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 15, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 11, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)